Nicole Daley

Ms. Daley’s recent client representations include the following:

IPOs and Capital Markets Transactions

• Achilles Therapeutics (United Kingdom) in its $175.5 initial public offering. 
• Esperion Therapeutics in connection with a 144A offering of $280 million aggregate principal amount of convertible senior subordinated notes and a concurrent capped call transaction and prepaid forward stock purchase transaction.
• AlloVir in its $317.7 million initial public offering. 
• Deciphera Pharmaceuticals in its $175 million follow-on public offering.
• Karuna Therapeutics in its $100 million initial public offering and its $250 million and $287.5 million follow-on offerings.
• BioDelivery Sciences International in its $60 million follow-on public offering. 
• Alnylam Pharmaceuticals in a $387.5 million follow-on public offering. 
  
   

Private Financings

• Imvaq Therapeutics in its $15 million Series B Preferred Stock and convertible note financing. 
• Beta Bionics in its $63 million Series B2 financing.
• Karuna Therapeutics in its $82 million Series B financing.
• Thrive Earlier Detection Corp. in its $110 million Series A financing.

Joint Ventures, M&A and Collaborations

• Plug Power in a $1.5 billion equity investment in connection with its strategic partnership with South Korea-based SK Group.
• Thrive Earlier Detection Corp. in its acquisition by Exact Sciences Corporation for up to $2.15 billion.
• Information Tycoon, the innovator of digital due diligence in multifamily real estate, in its acquisition by SightPlan.
• Unum Therapeutics in the sale of its BOXR (Bolt-on Chimeric Receptor) technology for approximately $11.5 million.
• Unum Therapeutics in its acquisition of Kiq LLC, a privately held, biotechnology company focused on the discovery and development of precision kinase inhibitors, and concurrent PIPE investment to raise $104 million.
• Avadel Legacy Pharmaceuticals, a wholly-owned subsidiary of Avadel Pharmaceuticals (Ireland), in the sale of its hospital product assets for approximately $40 million.
• Alnylam Pharmaceuticals in a $100 million equity financing closed in connection with its $2 billion strategic financing collaboration with Blackstone.
• CRISPR Therapeutics in a series of transactions by which CRISPR acquired 100% of the partnership interests of Casebia Therapeutics.
• BeiGene in its $2.7 billion share sale as part of a global strategic collaboration with Amgen.
• BlueRock Therapeutics on its agreement to be fully acquired by Bayer AG for up to $1 billion.
• Ultragenyx Pharmaceutical Inc. on its partnership with GeneTx Biotherapeutics LLC to develop GeneTx’s GTX-102.
• Arvinas, Inc. in its collaboration with Bayer to jointly launch a new company to leverage Arvinas’ PROTAC technology for agricultural applications.
• Alnylam Pharmaceuticals in a $400 million equity financing closed in connection with Alnylam’s collaboration with Regeneron Pharmaceuticals.